RAM
APLS

Readystate Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Readystate Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,800
Closed -$517K – 707
2024
Q1 		$517K Buy
+8,800
New +$561K 0.01% 799

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Readystate Asset Management's APLS Position: Q1 2026 in Review

Readystate Asset Management opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 34,100 shares worth $1.37M. The stake represents 0.06% of the portfolio and ranks #201 among its holdings. This is a return to the name: Readystate Asset Management previously reported a position in APLS as recently as Q3 2025.

Readystate Asset Management first reported a position in APLS in Q1 2024 and has held it in 4 quarters since. The position peaked at $5.48M in Q3 2025. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Readystate Asset Management held 34,100 shares of Apellis Pharmaceuticals worth $1.37M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Readystate Asset Management position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.06% of Readystate Asset Management's portfolio in Q1 2026, its #201 holding.
  • Readystate Asset Management first reported a position in Apellis Pharmaceuticals in Q1 2024 and has held it in 4 quarters since.
  • Readystate Asset Management's Apellis Pharmaceuticals position peaked at $5.48M in Q3 2025.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.